TAC-T cell

TAC-T cell (T-cell Antigen Coupler T cell) is a novel form of genetically engineered autologous or allogeneic T-cell therapy developed to treat cancer. Unlike CAR-T cells that use synthetic receptors to activate immune responses, the TAC (T-cell Antigen Coupler) technology incorporates a chimeric receptor into patient-derived or donor-derived T cells that redirects them to recognize specific tumor antigens and activates them through the natural endogenous TCR signaling pathway[2][3][4]. This approach aims to provide more physiologic activation of the immune response with potentially fewer side effects than traditional CAR-T therapies[3][6]. The technology allows for targeting various tumor-associated antigens such as HER2 (in solid tumors like breast and gastric cancer), CLDN18.2 (in gastrointestinal cancers), CD19 (in B-cell malignancies), and BCMA (in multiple myeloma)[4][7][8][9]. Early clinical trials have shown promising safety profiles with manageable toxicities and encouraging efficacy signals in heavily pretreated patients with solid tumors and hematological malignancies[5][6][10].

Other names

Chinese name: TAC-T细胞